Patent №
US 11,615,324
Granted
2023-03-28
Filed 2021
Owner
RO5 INC.
Lab
—
AI components
4
ml · vision · kr · hardware
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
17174677
A system and method for de novo drug discovery using machine learning algorithms. In a preferred embodiment, de novo drug discovery is performed via data enrichment and interpolation/perturbation of molecule models within the latent space, wherein molecules with certain characteristics can be generated and tested in relation to one or more targeted receptors. Filtering methods may be used to determine active novel molecules by filtering out non-active molecules and contain activity predictors to better navigate the molecule-receptor domain. The system may comprise neural networks trained to reconstruct known ligand-receptors pairs and from the reconstruction model interpolate and perturb the model such that novel and unique molecules are discovered. A second preferred embodiment trains a variational autoencoder coupled with a bioactivity model to predict molecules exhibiting a range of desired properties.
AI classification
Ownership
RO5 INC.
assignment · 554640862
Assignors
PABRINKIS, AURIMAS, BUCHER, ALWIN, KAMUNTAVICIUS, GINTAUTAS, PRAT, ALVARO, BASTAS, ORESTIS, JOCYS, ZYGIMANTAS, TAL, ROY, KNUFF, CHARLES DAZLER
On an employer assignment, the assignors are typically the inventors.